Выпуск

What Psilocybin Depression Trials Actually Show

My Weird Prompts · 17 ноября 2026 г. · 26 мин

Compass Pathways has submitted COMP360 to the FDA after two Phase 3 trials hit their primary endpoints, yet the Week 6 advantage over placebo was just 3.6 MADRS points—half of the Week 1 peak. A look at the clinical evidence for psilocybin in treatment-resistant depression unpacks what the COMP005, COMP006, and EPIsoDE trials actually measured, why expectancy and functional unblinding complicate the results, and how much of the effect comes from the drug versus the therapy. Key sources: • Compass Pathways — https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx • Compass Pathways — https://s204.q4cdn.com/927483861/files/doc_downloads/2026/02/17/Phase-3-data-presentation-Q1-2026-draft_post-LSA-2.pdf • Compass Pathways — https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/ Episode 6648 — myweirdprompts.com/n/6648 (permanent short link: myweirdprompts.com/916120) Listen on Android: MWP FM Player — myweirdprompts.com/apk

Страница выпуска